TY - JOUR AU - Yang, Jin-Ji AU - Huang, Cheng AU - Chen, Gong-Yan AU - Song, Yong AU - Cheng, Ying AU - Yan, Hong-Hong AU - Zhou, Qing AU - Wu, Yi-Long PY - 2014 DA - 2014/09/20 TI - A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung JO - BMC Cancer SP - 684 VL - 14 IS - 1 AB - Recent advances have shown that histology and genetic biomarkers are important in patient selection, which have led to significantly better outcomes for lung cancer patients. However, most new treatments only apply to adenocarcinoma or non-squamous, and in squamous carcinoma there is little breakthrough. In a phase III trial nab-paclitaxel plus carboplatin showed superior response rate over paclitaxel and carboplatin. In subgroup analysis the squamous histology appeared to be a predictive factor to nab-paclitaxel treatment. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-14-684 DO - 10.1186/1471-2407-14-684 ID - Yang2014 ER -